Healthcare perspectives from The Economist Intelligence Unit

Color

#DB444B

Hero Carousel

Spotlight

Bringing healthcare to hard-hit areas in Bangladesh

YouTube

https://www.youtube.com/channel/UCQDMOSbJtqrtNzif5rS22OQ

Slideshare

http://www.slideshare.net/economistintelligenceunit

Pinterest

https://www.pinterest.com/theeiu/

Women’s health and well-being


How do definitions of women’s well-being vary by region, age and income? Our new infographic, sponsored by Merck Consumer Health explores.

Infographic | Breathing in a new era: a comparative analysis of lung cancer policies in Japan, South Korea and Taiwan

Country Infographics

Breathing in a new era: a comparative analysis of lung cancer policies in Japan, South Korea and Taiwan

Lung cancer is the most fatal cancer worldwide. By 2050 the global burden of lung cancer is projected to increase to 3.8m new cases and 3.2m deaths per year, with the greatest burden expected in East Asia, at 1.7m new cases and 1.5m deaths.1

The Economist Impact report, "Breathing in a new era: a comparative analysis of lung cancer policies in Japan, South Korea and Taiwan," sponsored by MSD, evaluates the various policies impacting lung cancer care in the three countries under the following five domains:

Biopharma’s evolution: learnings from the pandemic for a revived regulatory landscape

By December 2020, several potential covid-19 vaccines were showing promise in clinical trials. And by the middle of 2021, a vaccine was available to the public. Very few people had been optimistic that such a feat could be achieved. In many ways, it was a perfect storm. The fast development of covid-19 vaccines benefited from years of previous research on related viruses and vaccine trials that used mRNA. It’s said the research matured at just the right time, and that mRNA technology would not have been ready even five years ago.

The longevity equation: climate resilience for health in the Middle East

Climate change is one of the most complex threats to the health of our people and our planet. The Middle East is among the geographic areas most vulnerable to rising temperatures, air pollution, food and water insecurity and adverse weather events. Without considerable mitigation and adaptation efforts, the health and longevity of current and future generations will be severely impacted.

 

Musculoskeletal Injuries in Australia: Current Challenges and Opportunities

Musculoskeletal disorders (MSDs), affecting an estimated 1.71 billion people globally, are a leading cause of disability and rehabilitation needs, accounting for 149 million years lived with disability.1

The longevity equation: climate resilience for health in the Middle East

Climate change is one of the most complex threats to the health of our people and our planet. The Middle East is among the geographic areas most vulnerable to rising temperatures, air pollution, food and water insecurity and adverse weather events. Without considerable mitigation and adaptation efforts, the health and longevity of current and future generations will be severely impacted.

 

Tackling the challenges of antimicrobial resistance (AMR) in Africa

In the heart of the bustling Nigerian city of Lagos, under the relentless sun, stands a small pharmacy with a faded green sign. It’s a modest place, just a short walk away from my childhood home. As a child, I often wandered inside, not for sweets or toys, but in pursuit of something far more valuable—health.

Tackling antimicrobial resistance in healthcare: the significance of robust health and economic data

Antimicrobial resistance (AMR) ranks among the top ten global public health challenges.1 Partly driven by the inappropriate and injudicious use of antimicrobial agents, AMR poses a significant threat.

Universal health, rare diseases and the promise of the UN Resolution

On an individual basis, rare diseases (RDs) can affect relatively small numbers of people. Collectively, however, they wage a significant burden—there are over 7,000 RDs and together they affect 300m people globally. The impact of RDs extends beyond their prevalence, stunting economic development the world over; although evidence on the economic burden in Europe is scarce, to provide perspective, in the US the annual costs of 15.5m people with 379 RDs equates to over US$1trn, with inpatient care and prescription medications driving 50% of total direct costs (US$449bn).

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week